Canaccord Genuity Group Raises Regulus Therapeutics (NASDAQ:RGLS) Price Target to $28.00

Regulus Therapeutics (NASDAQ:RGLS) had its price target upped by equities research analysts at Canaccord Genuity Group from $11.00 to $28.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also weighed in on the company. HC Wainwright upped their price objective on Regulus Therapeutics from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday. Leerink Partnrs reissued an “outperform” rating on shares of Regulus Therapeutics in a report on Monday, March 18th. Wells Fargo & Company boosted their target price on Regulus Therapeutics from $2.00 to $3.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 13th. StockNews.com started coverage on Regulus Therapeutics in a report on Tuesday, April 16th. They issued a “sell” rating on the stock. Finally, SVB Leerink started coverage on Regulus Therapeutics in a report on Monday, March 18th. They issued an “outperform” rating and a $6.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Regulus Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $11.75.

Regulus Therapeutics Trading Down 4.7 %

RGLS stock opened at $2.04 on Tuesday. Regulus Therapeutics has a 1-year low of $1.08 and a 1-year high of $3.79. The firm has a market cap of $133.56 million, a P/E ratio of -1.40 and a beta of 1.64. The business’s 50 day moving average is $2.25 and its 200-day moving average is $1.91.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.14). Sell-side analysts forecast that Regulus Therapeutics will post -0.59 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Vivo Capital LLC acquired a new position in Regulus Therapeutics during the 1st quarter worth $14,400,000. Victory Capital Management Inc. lifted its holdings in Regulus Therapeutics by 16.5% during the 4th quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock worth $348,000 after buying an additional 38,529 shares in the last quarter. FMR LLC lifted its holdings in Regulus Therapeutics by 32.4% during the 3rd quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock worth $4,033,000 after buying an additional 716,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Regulus Therapeutics by 158.4% during the 1st quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after buying an additional 453,784 shares in the last quarter. Finally, Opaleye Management Inc. acquired a new position in Regulus Therapeutics during the 1st quarter worth $490,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.